title: Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
abstract: Employers in the United States might not be aware of the productivity costs of migraine or the extent to which those costs can be reduced by optimal treatment. An economic model was developed to enable employers to estimate the productivity costs of migraine to their company and the savings that will accrue if those patients who suffer from migraine are treated with rizatriptan. Analyses were run for both a major financial services corporation and a representative U.S. company. The major financial services corporation, with 87,821 employees, is projected to lose 538 person-years annually, at an estimated cost of 23.8 million dollars. A representative U.S. company with 10,000 employees is projected to lose 46.0 person-years of productive effort annually as a result of migraine, valued at approximately 1.94 million dollars. The value of the annual work loss avoided if migraine is treated with rizatriptan is projected at 10.3 million dollars for the financial services corporation and 841,000 dollars for the representative U.S. company. There is a substantial productivity cost burden of migraine from a U.S. employer perspective. These productivity costs can be reduced significantly by treating migraine headaches with rizatriptan.
authors.affiliation: Worldwide Outcomes Research, Merck & Co., Inc., Whitehouse Station, New Jersey 08889, USA. william_gerth@merck.com
authors.forename: William C
authors.initials: WC
authors.lastname: Gerth
authors.forename: Syam
authors.initials: S
authors.lastname: Sarma
authors.forename: X Henry
authors.initials: XH
authors.lastname: Hu
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Silberstein
mesh_terms: D000041:Absenteeism; D000328:Adult; D003362:Cost-Benefit Analysis; D004526:Efficiency; D017049:Employer Health Costs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D018803:Models, Economic; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D014230:Triazoles / Q000191:economics / Q000627:therapeutic use*; D014363:Tryptamines; D014481:United States / Q000453:epidemiology; D017132:Workplace / Q000191:economics
chemical_list: D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan